Provided by Tiger Trade Technology Pte. Ltd.

uniQure NV

14.77
-0.8300-5.32%
Post-market: 15.060.2900+1.96%19:25 EDT
Volume:1.36M
Turnover:20.35M
Market Cap:920.05M
PE:-4.27
High:15.83
Open:15.55
Low:14.58
Close:15.60
52wk High:71.50
52wk Low:7.76
Shares:62.29M
Float Shares:40.64M
Volume Ratio:0.52
T/O Rate:3.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4602
EPS(LYR):-3.4602
ROE:-207.10%
ROA:-16.21%
PB:4.63
PE(LYR):-4.27

Loading ...

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

GlobeNewswire
·
Mar 02

Uniqure NV expected to post a loss of 95 cents a share - Earnings Preview

Reuters
·
Feb 27

RBC Capital says Makary comments on uniQure gene therapy approach disappointing

TIPRANKS
·
Feb 27

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY) and uniQure (QURE)

TIPRANKS
·
Feb 27

Stifel says uniQure ‘understandably’ under pressure on Makary comments

TIPRANKS
·
Feb 27

Class Action Lawsuit Targets uniQure NV Investors

Reuters
·
Feb 26

Rosen Law Firm Sets April 13 Lead Plaintiff Deadline in uniQure Securities Class Action

Reuters
·
Feb 26

Rosen Law Firm urges uniQure investors to act before April 13 lead plaintiff deadline

Reuters
·
Feb 25

uniQure Initiated at Peer Perform by Wolfe Research

Dow Jones
·
Feb 24

uniQure initiated with a Peer Perform at Wolfe Research

TIPRANKS
·
Feb 24

uniQure NV updated its financial calendar

Reuters
·
Feb 23

uniQure to Announce 2025 Financial Results

GlobeNewswire
·
Feb 23

Class Action Lawsuit Targets uniQure NV Over Alleged Securities Fraud

Reuters
·
Feb 18

Investors Sue uniQure NV Over Alleged Misleading Disclosures

Reuters
·
Feb 17

uniQure Faces Class Action Over Alleged Misleading Statements on Drug Approval

Reuters
·
Feb 14

Assessing uniQure (QURE) Valuation After New Securities Fraud Lawsuit On AMT-130 Disclosures

Simply Wall St.
·
Feb 12

uniQure Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 10

How Early AMT-191 Gene Therapy Signals Will Impact uniQure (QURE) Investors

Simply Wall St.
·
Feb 09

Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch

Benzinga_recent_news
·
Feb 07

uniQure präsentiert neue Phase-I/IIa-Daten zur Gentherapie AMT-191 bei Fabry-Krankheit

Reuters
·
Feb 06